FIGURE 6.

VEGFR2 is highly expressed in oncogene‐driven NSCLC cells. A, qRT‐PCR of VEGFR2 in PC‐9, H3255, ABC‐11, H3122, HCC78, and ABC‐20 cells. GAPDH was used as the reference gene. Data are presented as means ± standard error. B, Clinical specimens of tumors bearing EGFR mutations exhibited higher levels of VEGFR2 expression than did EGFR‐wild‐type tissues, as revealed by immunostaining. C, Increased VEGFR2 expression induced by treatment with erlotinib, alectinib, or crizotinib in accordance with qRT‐PCR. PC‐9, ABC‐11, and ABC‐20 cells were treated with erlotinib (100 nmol/L), alectinib (100 nmol/L), or crizotinib (1 μmol/L), respectively, for 24 h. Data are presented as means ± SE